← Back to Search

NMDA-R Antagonist

Memantine Hydrochloride for Subdural Hematoma (TASD Trial)

Phase < 1
Waitlist Available
Research Sponsored by University of New Mexico
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Surgical intervention for chronic or subacute SDH
Age 18-100
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

TASD Trial Summary

This trial will explore how to reduce brain swelling and improve neurological function in older adults with cSDH.

Who is the study for?
This trial is for adults aged 18-100 who've had surgery for chronic subdural hematoma and experienced spreading depolarization within 48 hours post-operation. They must have an electrode strip placed during surgery. It's not for those with severe liver or kidney issues, known allergies to memantine, current memantine users, women not using dual contraception, or patients needing large craniotomy.Check my eligibility
What is being tested?
The TASD study is testing if Memantine Hydrochloride can reduce neurological problems like weakness or confusion after cSDH surgery by blocking certain brain signals (NMDA-R antagonism). Some participants will get the real drug while others a placebo to compare outcomes.See study design
What are the potential side effects?
Memantine may cause side effects such as dizziness, headache, constipation, and confusion. Since it affects the brain directly, it might also influence mood and behavior but varies from person to person.

TASD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had surgery for a slow bleeding in my brain.
Select...
I am between 18 and 100 years old.
Select...
My surgical site infection was identified within 2 days after surgery.

TASD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
90 day eGOS
Spreading depolarizations and seizures
Secondary outcome measures
Neurological deficits: Incidence of new motor weakness or new dysphagia
Safety

Side effects data

From 2011 Phase 2 trial • 29 Patients • NCT00585169
10%
Headache
7%
Light-headed/dizzy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Memantine 10mg
Memantine 30mg
Memantine 20mg

TASD Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MemantineExperimental Treatment1 Intervention
Subjects will be given memantine 10mg PO/ NG BID for 7 days
Group II: PlaceboPlacebo Group1 Intervention
Subjects will be given identical placebo syrup PO/NG BID for 7 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Memantine Hydrochloride
2018
Completed Phase 2
~170

Find a Location

Who is running the clinical trial?

University of New MexicoLead Sponsor
372 Previous Clinical Trials
3,528,769 Total Patients Enrolled

Media Library

Memantine Hydrochloride (NMDA-R Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT04966546 — Phase < 1
Subdural Hematoma Research Study Groups: Memantine, Placebo
Subdural Hematoma Clinical Trial 2023: Memantine Hydrochloride Highlights & Side Effects. Trial Name: NCT04966546 — Phase < 1
Memantine Hydrochloride (NMDA-R Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04966546 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the permissible age range for this trial participants above thirty years?

"The boundaries for the trial's inclusion criteria are 18 years old and 100 years old."

Answered by AI

Have any other research initiatives been conducted that involve Memantine?

"Currently, there are 26 live studies being conducted for Memantine, 10 of which have advanced to Phase 3. The primary research hub is located in Irvine California; however, a total 448 sites across the world are conducting trials on this medication."

Answered by AI

Who meets the criteria to participate in this investigation?

"To gain admittance to this clinical trial, a patient must have been diagnosed with subdural hematoma and be aged between 18-100 years. The study is currently attempting to enrol approximately 20 individuals."

Answered by AI

Are there currently opportunities to sign up for this scientific experiment?

"Clinicaltrials.gov confirms that this trial has terminated its recruitment phase, with the last update taking place on May 24th 2023. However, there are 86 other medical studies actively seeking out volunteers at present."

Answered by AI

How many individuals are eligible to take part in this experiment?

"Unfortunately, this particular trial has concluded its recruitment of participants. It was first posted to clinicaltrials.gov on June 1st 2022 and last modified on May 24th 2023. For those still interested in finding trials related to subdural hematoma or Memantine, there are 60 and 26 studies respectively that remain open for patient enrollment."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)
Andrew Phillip Carlson 2022. "Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04966546.
~9 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top